etrials

Etrials Pays $500K to Terminate Agreement with BioClinica

Wednesday, June 3, 2009 07:00 AM

Only days after BioClinica increased its purchase offer to acquire etrials Worldwide and the two companies agreed to proceed with their acquisition agreement, that agreement has been terminated.

More... »


BioClinica Increases Offer to Buy etrials Worldwide

Thursday, May 21, 2009 08:30 AM

BioClinica, formerly Bio-Imaging Technologies, increased the value of its offer to acquire troubled eClinical vendor etrials Worldwide in response to an unsolicited offer received by etrials from an unrelated third party.

More... »


etrials Cuts Costs—and Losses in Q1

Wednesday, May 13, 2009 08:58 AM

eClinical vendor etrials Worldwide cut its net loss for the first quarter 2009 in half from the same period 2008 by reducing operating expenses, the company said. Net loss for Q1 was $960,000, compared with $2 million in Q1 2008—and $5.5 million in the fourth quarter 2008.

More... »

Bio-Imaging to Acquire etrials

Tuesday, May 5, 2009 08:40 AM

Only a week after Bio-Imaging Technologies announced a name change to BioClinica and alluded to future acquisitions, the contract research organization (CRO) announced this morning its intent to acquire troubled eClinical vendor etrials Worldwide.

More... »

ClearTrial Appoints New COO

Friday, March 27, 2009 11:17 AM

ClearTrial, a provider of clinical trial software, appointed Michael Bruns as the company’s new chief operating officer. Bruns will oversee ClearTrial’s global operations and help further develop and implement the company’s growth strategy. Prior to joining ClearTrial, Bruns was director of the Technology Investment Banking Group at Robert W. Baird, a global investment banking firm.

More... »

etrials Ends 'Challenging Year,' Reports $15.8M Loss

Friday, March 6, 2009 07:59 AM

In what CEO M. Denis Connaghan called a "challenging year," eClinical company etrials reported a decrease in year-end revenue and an operating loss for the year.

More... »

Etrials Restructuring—Again

Monday, December 22, 2008 11:13 AM

A month after naming a new permanent CEO, beleaguered eClinical company etrials is reorganizing its management structure—a move that will result in the departure of once-interim CEO Chuck Piccirillo as well as two other senior executives.

More... »

Etrials Appoints Permanent CEO

Friday, November 14, 2008 09:00 AM

Just a day after releasing disappointing third quarter results, Morrisville, N.C.-based eClinical company etrials named a new president and CEO, M. Denis Connaghan, replacing interim president and CEO Chuck Piccirillo. Piccirillo, who will resume his position as vice president of technology, has served as interim CEO since the resignation of Eugene “Chip” Jennings in July. Connaghan was formerly managing director within Marsh USA’s Global Operations.

More... »

etrials Reports $6.1M Loss

Wednesday, November 12, 2008 10:10 AM

Morrisville, N.C.-based eClinical company etrials reported another quarter of loss, with net losses for the third quarter at $6.1 million, compared with $1.3 million for the same period last year and $2.2 million in net losses for the second quarter of 2008.

More... »

Former etrials COO Named PDS President

Thursday, October 2, 2008 12:08 PM

Former etrials chief operating officer Peter S. Benton is the newly named president of Phoenix Data Systems (PDS), the eClinical division of Newtown, Pa.-based CRO Bio-Imaging Technologies. Benton, whose position at etrials was eliminated in April, will succeed Dr. William Claypool, who is leaving PDS to start a pharmaceutical development consulting company. Bio-Imaging acquired PDS earlier this year.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs